Shan Minghui, Cheng Qiong, Parris Amanda B, Kong Lingfei, Yang Xiaohe, Shi Yujie
Department of Pathology, People's Hospital of Zhengzhou University, Zhengzhou, Hena, China.
Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Front Cell Dev Biol. 2024 Jul 11;12:1427395. doi: 10.3389/fcell.2024.1427395. eCollection 2024.
Metformin shows promise in breast cancer prevention, but its underlying mechanisms remain unclear. This study investigated the impact of metformin on the repopulation dynamics of mammary epithelial cells (MECs) and the signaling pathways in non-tumorigenic FVB/N mice. This study aimed to enhance our understanding of the role of metformin in reducing the susceptibility of MECs in premalignant tissues to oncogenic factors. In this study, female mice were administered 200 mg/kg/day of metformin via intraperitoneal (i.p.) injection from 8 to 18 weeks of age. After this treatment period, morphogenesis, flow cytometry, analyses of MEC stemness, and RNA sequencing were performed. The study findings indicated that metformin treatment in adult mice reduced mammary gland proliferation, as demonstrated by decreased Ki67+ cells and lateral bud formation. Additionally, metformin significantly reduced both basal and mammary repopulating unit subpopulations, indicating an impact on mammary epithelial cell repopulation. Mammosphere, colony-forming cell, and 3D culture assays revealed that metformin adversely affected mammary epithelial cell stemness. Furthermore, metformin downregulated signaling in key pathways including AMPK/mTOR, MAPK/Erk, PI3K/Akt, and ER, which contribute to its inhibitory effects on mammary proliferation and stemness. Transcriptome analysis with RNA sequencing indicated that metformin induced significant downregulation of genes involved in multiple critical pathways. KEGG-based pathway analysis indicated that genes in PI3K/Akt, focal adhesion, ECM-receptor, small cell lung cancer and immune-modulation pathways were among the top groups of differentially regulated genes. In summary, our research demonstrates that metformin inhibits MEC proliferation and stemness, accompanied by the downregulation of intrinsic signaling. These insights suggest that the regulatory effects of metformin on premalignant mammary tissues could potentially delay or prevent the onset of breast cancer, offering a promising avenue for developing new preventive strategies.
二甲双胍在乳腺癌预防方面显示出前景,但其潜在机制仍不清楚。本研究调查了二甲双胍对非致瘤性FVB/N小鼠乳腺上皮细胞(MECs)再增殖动力学及信号通路的影响。本研究旨在加深我们对二甲双胍在降低癌前组织中MECs对致癌因素易感性方面作用的理解。在本研究中,雌性小鼠从8周龄至18周龄通过腹腔内(i.p.)注射给予200mg/kg/天的二甲双胍。在该治疗期后,进行了形态发生、流式细胞术、MEC干性分析和RNA测序。研究结果表明,成年小鼠接受二甲双胍治疗后乳腺增殖减少,表现为Ki67+细胞减少和侧芽形成减少。此外,二甲双胍显著降低了基础和乳腺再增殖单位亚群,表明对乳腺上皮细胞再增殖有影响。乳腺球、集落形成细胞和三维培养试验表明,二甲双胍对乳腺上皮细胞干性有不利影响。此外,二甲双胍下调了包括AMPK/mTOR、MAPK/Erk、PI3K/Akt和ER在内的关键通路中的信号传导,这有助于其对乳腺增殖和干性的抑制作用。RNA测序的转录组分析表明,二甲双胍诱导参与多个关键通路的基因显著下调。基于KEGG的通路分析表明,PI3K/Akt、粘着斑、细胞外基质受体、小细胞肺癌和免疫调节通路中的基因是差异调节基因的前几组。总之,我们的研究表明,二甲双胍抑制MEC增殖和干性,同时下调内在信号传导。这些见解表明,二甲双胍对癌前乳腺组织的调节作用可能会延迟或预防乳腺癌的发生,为开发新的预防策略提供了一条有前景的途径。